Shore Capital Reiterates Buy Rating for Uniphar (LON:UPR)

Uniphar (LON:UPRGet Free Report)‘s stock had its “buy” rating restated by investment analysts at Shore Capital in a report released on Tuesday,London Stock Exchange reports.

Uniphar Price Performance

Shares of LON:UPR traded up GBX 17 ($0.21) during trading on Tuesday, hitting GBX 195 ($2.43). 48,700 shares of the company were exchanged, compared to its average volume of 20,728. The business’s 50 day moving average is GBX 174.62 and its 200-day moving average is GBX 198.80. The company has a market capitalization of £532.39 million, a P/E ratio of 1,392.86 and a beta of 0.75. The company has a quick ratio of 0.60, a current ratio of 0.90 and a debt-to-equity ratio of 119.43. Uniphar has a 1-year low of GBX 163 ($2.03) and a 1-year high of GBX 256 ($3.19).

Uniphar Company Profile

(Get Free Report)

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.

Featured Stories

Receive News & Ratings for Uniphar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniphar and related companies with MarketBeat.com's FREE daily email newsletter.